# Nephritic Syndrome Workup

Evaluate suspected nephritic syndrome by confirming glomerular hematuria, quantifying kidney injury and proteinuria, identifying immediately reversible threats, then using complement and targeted serologies to direct urgent kidney biopsy and cause-specific management.

**Clinical question:** How should clinicians rapidly confirm nephritic syndrome, identify its cause, and determine when kidney biopsy is required?

Updated: 2026-09-15T21:49:41.448747+00:00

## What matters in practice
- Treat a nephritic urine sediment with acute kidney dysfunction, oliguria, hypertension, edema, or rapidly changing creatinine as suspected active glomerulonephritis until proven otherwise. [4][13][18]
- Confirm glomerular hematuria with urine microscopy: at least 40% dysmorphic erythrocytes, at least 5% acanthocytes, or at least 1 RBC cast per 50 low-power fields is a practical high-specificity threshold. [9]
- Order C3 and C4 early: low complement favors immune-complex or complement-mediated disease, whereas anti-GBM and pauci-immune GN usually have normal complement levels. [10][12]
- Use concurrent targeted serologies—ANA, anti-dsDNA, ANCA, anti-GBM antibodies, streptococcal serologies, and infection assessment—to distinguish treatable etiologies while arranging kidney biopsy. [3][10][12]
- Kidney biopsy is the diagnostic gold standard for glomerular disease and is generally needed in nephritic presentations because clinical and serologic patterns do not reliably establish histology. [4][6]

## Identify the nephritic presentation that requires urgent evaluation

Prioritize renal trajectory and active urine sediment over the degree of visible hematuria.

Suspect nephritic syndrome when hematuria accompanies proteinuria plus hypertension, edema, oliguria, or impaired kidney function. A rapidly progressive fall in kidney function with a nephritic urine picture is the clinical syndrome of rapidly progressive glomerulonephritis and should accelerate nephrology involvement and biopsy planning. [4][13][18]

At presentation, obtain blood pressure, weight, urine output history, serum creatinine, electrolytes, serum albumin, urinalysis with microscopy, and quantitative protein excretion. These data separate an inflammatory glomerular process from isolated nonglomerular hematuria, define the severity of kidney dysfunction, and identify mixed nephritic-nephrotic presentations that occur with disorders such as membranoproliferative GN. [12][13]

Review the time course and systemic clues before interpreting serologies. Recent or ongoing infection supports infection-related GN; episodic flares are characteristic of IgA nephropathy and C3 glomerulopathy; pulmonary hemorrhage or rapidly progressive GN raises concern for anti-GBM disease; and systemic autoimmune features should prompt evaluation for lupus or ANCA-associated vasculitis. [3][10]
- Document oliguria and serial creatinine because worsening renal function changes the urgency of biopsy and disease-directed treatment. [4][13]
- Record hypertension and edema as manifestations of salt-water retention in nephritic disease; assess for pleural effusion or ascites when volume excess is clinically suspected. [12]
- Ask specifically about prescribed, over-the-counter, herbal, and home remedies; medication and exposure histories can provide etiologic clues in glomerular disease evaluation. [17]

*Clinical findings that distinguish a nephritic urine syndrome from a predominantly nephrotic presentation. [11][12][13]*

| Finding | Nephritic pattern | Predominantly nephrotic pattern | Immediate diagnostic implication |
| --- | --- | --- | --- |
| Urine sediment | Dysmorphic RBCs and RBC casts; WBC casts may accompany proliferative GN. [9][10][12] | Oval fat bodies and lipiduria favor a glomerular permeability disorder with nephrotic syndrome. [11][12] | An active RBC sediment directs serologic evaluation for inflammatory GN and usually biopsy. [4][6] |
| Proteinuria | Usually subnephrotic but may be nephrotic in some proliferative lesions. [4][12] | Heavy proteinuria; nephrotic syndrome is defined by protein excretion greater than 3.0 g per 24 hours with hypoalbuminemia and edema. [13][15] | Quantify proteinuria rather than relying on dipstick alone; mixed features broaden the differential. [11][13] |
| Hemodynamics and kidney function | New or accelerated hypertension, oliguria, edema, and reduced kidney function are typical. [4][12][18] | Edema, hypoalbuminemia, hyperlipidemia, and thrombosis may dominate; intravascular volume may be low or high. [13][14] | Assess volume status before treating edema because nephrotic patients may be underfilled or overfilled. [14] |

## Use urine microscopy to establish glomerular hematuria

A properly examined sediment is the fastest discriminator between glomerular and many urologic causes of hematuria.

Request fresh urine microscopy with explicit assessment for RBC morphology, acanthocytes, RBC casts, WBC casts, renal tubular epithelial cells, and renal tubular epithelial cell casts. A reasonable definition of glomerular hematuria is at least 40% dysmorphic RBCs, at least 5% acanthocytes, or at least 1 RBC cast per 50 low-power fields. [9]

A lower dysmorphic-RBC cutoff of at least 25% had sensitivity of 20.4% and specificity of 96.3% for glomerular disease in one study; therefore, a negative or weakly positive dysmorphic-RBC assessment does not exclude GN. Isomorphic RBCs may occur in GN and also in acute interstitial nephritis, renal cell carcinoma, nephrolithiasis, urinary tract infection, and excessive anticoagulation. [9]

Interpret pyuria in context. WBC casts or pyuria together with dysmorphic RBCs or RBC casts favor proliferative GN, whereas tubular epithelial cells and casts may reflect concurrent tubular injury in acute nephritic syndrome. [9]
- Quantify proteinuria with a timed collection when an accurate daily measurement is needed; 3+ urine dipstick protein is approximately 300 mg/dL and correlates with daily losses of 3 g or more. [11]
- Look for lipiduria or oval fat bodies when edema and heavy proteinuria suggest a nephrotic component. [11][12]
- Do not attribute hematuria to a urinary tract process solely because dysuria, pyuria, or anticoagulant exposure is present; assess sediment morphology and kidney function. [9]

*Urine sediment findings and the next diagnostic action. [9][10][12]*

| Sediment finding | Interpretation | Next step |
| --- | --- | --- |
| At least 5% acanthocytes or at least 1 RBC cast per 50 low-power fields | Strongly supports glomerular hematuria. [9] | Proceed with serum creatinine, protein quantification, complement testing, targeted serologies, and nephrology-directed biopsy planning. [6][10][12] |
| At least 40% dysmorphic RBCs | Practical threshold for glomerular hematuria; morphology is specific but incompletely sensitive. [9] | Do not defer GN evaluation because proteinuria is modest or creatinine is initially preserved. [4][9] |
| Dysmorphic RBCs plus WBC casts or pyuria | More suggestive of proliferative GN than nonproliferative glomerular disease. [9] | Prioritize immune-complex, complement-mediated, lupus, infection-related, and vasculitic etiologies. [3][12] |
| Oval fat bodies or lipiduria | Supports a nephrotic pattern of glomerular injury. [11][12] | Assess serum albumin, heavy proteinuria, edema, and thrombotic manifestations; consider a mixed syndrome if hematuria or RBC casts coexist. [12][13] |

## Use complement and serologies to narrow the glomerulonephritis differential

Draw disease-defining studies promptly; results guide pathology interpretation but do not replace biopsy.

Obtain C3 and C4 before kidney biopsy whenever feasible. Hypocomplementemia directs the differential toward immune-complex and complement-mediated GN, including infection-related GN, lupus nephritis, cryoglobulinemic GN, and C3 glomerulopathy. Normal complement is more typical of anti-GBM disease, pauci-immune GN, and monoclonal immunoglobulin-associated GN, although monoclonal immunoglobulin disease can occasionally be hypocomplementemic and mimic C3 GN. [3][10][12]

Order ANA and anti-dsDNA antibodies when lupus is plausible clinically or when complement is low. Order ANCA when pauci-immune vasculitis is possible, particularly with rapidly progressive kidney dysfunction or systemic vasculitic manifestations. Order circulating anti-GBM antibodies immediately when rapidly progressive GN or alveolar hemorrhage is present. [3][5][10]

For a possible poststreptococcal process, measure antistreptolysin O and anti-DNase B titers; elevated levels support recent streptococcal infection. In suspected infection-related GN, evaluate for active infection, including infective endocarditis when the clinical setting supports it, because both poststreptococcal disease and endocarditis-associated GN can have low complement. [10]
- A nephritic flare temporally associated with mucosal infection supports IgA nephropathy, but kidney biopsy establishes the diagnosis through IgA-dominant or codominant mesangial deposits. [3][5]
- Do not equate an MPGN pattern with a single disease: hepatitis C, alternative complement pathway abnormalities, infection, lupus, cryoglobulinemia, and monoclonal processes can produce overlapping proliferative patterns. [3]
- If routine biopsy immunofluorescence suggests C3 GN but the clinical pattern raises concern for monoclonal immunoglobulin disease, pathology may require pronase treatment of paraffin-embedded tissue to uncover masked monoclonal deposits. [12]

*Complement-based diagnostic branches for nephritic syndrome. [3][10][12]*

| Laboratory branch | Priority etiologies | Tests that refine the branch | What changes next |
| --- | --- | --- | --- |
| Low C3 and/or C4 | Immune-complex GN, infection-related GN, lupus nephritis, cryoglobulinemic GN, and C3 glomerulopathy. [3][10][12] | ANA, anti-dsDNA, streptococcal serologies, infection evaluation, and kidney biopsy with immunofluorescence. [10][12] | Correlate with biopsy deposits and investigate or treat an active infection before assuming primary immune disease. [3][10] |
| Normal C3 and C4 | Pauci-immune ANCA-associated GN, anti-GBM disease, and monoclonal immunoglobulin-associated GN. [12] | ANCA, anti-GBM antibodies, and kidney biopsy with immunofluorescence. [10][12] | Rapidly progressive loss of kidney function or pulmonary hemorrhage warrants urgent nephrology coordination and expedited tissue diagnosis. [3][5] |
| Hypocomplementemia with C3-dominant pathology or atypical course | C3 glomerulopathy or monoclonal immunoglobulin-associated disease affecting the alternative complement pathway. [3][12] | Pathology review; consider pronase-based evaluation of paraffin-embedded tissue for masked monoclonal deposits. [12] | Avoid assigning a complement-mediated diagnosis until monoclonal deposits are adequately excluded. [12] |

## Arrange kidney biopsy when nephritic syndrome is confirmed or strongly suspected

Biopsy converts a clinical syndrome into a treatment-relevant pathologic diagnosis.

Kidney biopsy is the gold standard for diagnosing glomerular diseases and is generally necessary in nephritic syndrome because proliferative patterns have a broad differential and overlapping clinical presentations. [4][6] Expedite biopsy when kidney function is rapidly declining, the sediment is active with RBC casts, serologies suggest anti-GBM disease or ANCA-associated vasculitis, or the presentation combines nephritic and nephrotic features. [3][4][13]

Request interpretation integrating light microscopy, immunofluorescence, and clinical serologies. Immunofluorescence patterns help infer etiology: immune-complex GN includes infection-related GN, IgA nephropathy, lupus nephritis, and cryoglobulinemic GN; pauci-immune GN is associated with ANCA vasculitis; anti-GBM disease shows linear IgG deposition along the GBM; and C3 glomerulopathy is complement mediated. [3][5]

Do not rely on a single histologic label without etiologic correlation. MPGN and diffuse proliferative GN are patterns of injury that can arise from infection, lupus, cryoglobulinemia, hepatitis C, complement dysregulation, or monoclonal immunoglobulin disease. The pathology report should therefore be reconciled with complement studies, infection assessment, autoimmune serologies, and monoclonal-protein evaluation when indicated by the biopsy pattern. [3][12]
- Biopsy-proven anti-GBM disease may be defined by crescentic GN with linear IgG deposition along the GBM when no alternative cause explains the findings. [5]
- IgA nephropathy requires IgA-dominant or codominant mesangial immunoglobulin deposits for diagnosis. [5]
- If clinical urgency is high, draw serologies before disease-directed immunotherapy when feasible, but do not postpone urgent nephrology assessment solely to await results. [3][5][10]

*Pathology-oriented interpretation of major nephritic etiologies. [3][5][12]*

| Pathologic or immunologic category | Representative diseases | Corroborating clinical tests | Key diagnostic caution |
| --- | --- | --- | --- |
| Immune-complex GN | Infection-related GN, IgA nephropathy, lupus nephritis, cryoglobulinemic GN. [3] | C3/C4, ANA, anti-dsDNA, infection testing, streptococcal serologies when appropriate. [10][12] | Similar diffuse proliferative lesions may result from infection, lupus, or cryoglobulinemia. [3] |
| Pauci-immune GN | ANCA-associated vasculitis. [3] | ANCA testing; assess for systemic vasculitic manifestations and rapidly progressive renal failure. [3][10] | Normal complement supports but does not establish this category; biopsy remains decisive. [12] |
| Anti-GBM GN | Anti-GBM disease. [3][5] | Circulating anti-GBM antibodies; assess for alveolar hemorrhage. [5][10] | Urgent presentation may be renal-pulmonary or kidney limited. [5] |
| Complement-mediated GN | C3 glomerulopathy. [3] | C3/C4 and pathology review; evaluate for masked monoclonal deposits when indicated. [12] | Monoclonal immunoglobulin disease can mimic C3 GN and may be hypocomplementemic. [12] |

## Stabilize hypertension, volume excess, and kidney complications without obscuring the diagnosis

Supportive measures address immediate risk; disease-modifying therapy should follow the suspected etiologic branch and biopsy strategy.

Manage clinically significant hypertension, edema, oliguria, and deteriorating kidney function in parallel with the diagnostic evaluation. Nephritic syndrome is associated with salt-water retention, hypertension, edema, and reduced kidney function; reassess blood pressure, body weight, urine output, serum creatinine, and electrolytes as the clinical course evolves. [4][12][13]

Avoid treating all edema as equivalent. Nephrotic physiology can be associated with either intravascular underfilling from albumin loss or overfill from increased tubular sodium absorption; determine volume status before using therapies intended to remove fluid. [14] When nephrotic-range proteinuria coexists, serum albumin below 3.0 g/dL with protein excretion above 3.0 g per 24 hours supports nephrotic syndrome and should prompt assessment for thrombotic manifestations. [13][15]

Escalate rapidly when renal function declines over days to weeks, urine output falls, RBC casts persist, or pulmonary hemorrhage is suspected. These features shift the working diagnosis toward crescentic processes such as ANCA-associated or anti-GBM GN and justify urgent nephrology-led biopsy and treatment decisions. [3][5][13]
- Trend creatinine and urine output to detect rapidly progressive GN rather than relying on a single creatinine value. [4][13]
- Trend urine microscopy and hematuria as treatment-response markers after a diagnosis and therapy plan are established. [9]
- In advanced oliguric or anuric renal injury, renal replacement therapy may be required. [17]

*Monitoring targets during the diagnostic interval. [4][9][12][13][17]*

| Parameter | Why it matters | Escalation signal |
| --- | --- | --- |
| Serum creatinine and urine output | Defines the renal trajectory and identifies rapidly progressive renal failure. [4][13] | Rapid deterioration or oliguria should expedite nephrology evaluation and biopsy. [3][13] |
| Blood pressure, weight, and edema | Tracks salt-water retention and clinical volume burden. [12][13] | Accelerated hypertension or progressive edema requires active stabilization while etiologic studies proceed. [4][12] |
| Urine sediment | RBC casts, dysmorphic RBCs, and hematuria can support diagnosis and help assess response to treatment. [9][10] | Persistent active sediment with worsening kidney function supports ongoing glomerular inflammation. [4][9] |
| Pulmonary symptoms | Alveolar hemorrhage with rapidly progressive GN raises concern for anti-GBM disease. [5] | Urgently coordinate nephrology assessment, anti-GBM testing, and tissue diagnosis. [5][10] |

## References
1. Glomerulonephritis: immunopathogenesis and immunotherapy | Nature Reviews Immunology — www.nature.com — https://www.nature.com/articles/s41577-022-00816-y
2. Glomerular Disease Pathophysiology and Clinical Outcomes | Nephrology and Urology | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/glomerular-disease-pathophysiology-and-clinical-outcomes
3. Acute glomerulonephritis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0140673622004615
4. Nephritic Syndrome - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/nephritic-syndrome
5. POSTER PRESENTATION : Indian Journal of Nephrology — journals.lww.com — https://journals.lww.com/ijon/fulltext/2022/32001/poster_presentation.2.aspx
6. The Cleveland Clinic Kidney Biopsy Epidemiological Project — journals.lww.com — https://journals.lww.com/kidney360/_layouts/15/oaks.journals/downloadpdf.aspx?an=02200512-202212000-00012
7. Epidemiology and Outcomes of Glomerular Diseases in Low — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S027092952300013X
8. Nephritic Syndrome - an overview | ScienceDirect Topics — sciencedirect.com — https://sciencedirect.com/topics/medicine-and-dentistry/nephritic-syndrome
9. Diagnostic Utility of Urine Microscopy in Kidney Diseases — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11303840
10. Nephritic Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK562240
11. Nephrotic Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK470444
12. A beginner’s guide to the clinical approach and key concepts of glomerular disease: a mini review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12919384
13. Clinical Presentation & Management of Glomerular Diseases: Hematuria, Nephritic & Nephrotic Syndrome - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6188440
14. Minimal Change Disease - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK560639
15. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/21462608
16. An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11504437
17. Membranous Nephropathy - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK559169
18. Nephritic Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/sites/books/NBK562240

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.